Abstract
As well as being a passive support, the extracellular matrix also regulates key biological processes such as invasion, differentiation and angiogenesis. We have therefore developed an in vitro model of bladder cancer invasion using de-epithelialized rat bladder to allow for tumour cell–extracellular matrix interactions. Onto this we have seeded a panel of human bladder cancer cell lines (RT4, RT112, 253J and EJ28 (T24)) representing progression from well to poorly differentiated phenotypes and used as models of superficial to invasive bladder cancer. The better differentiated cell lines RT4 and RT112 reproducibly grew as stratified epithelium, whereas poorly differentiated EJ28 cells invaded across a broad front. Invasion was not simply related to proliferation rate, measured either as doubling time on plastic (non-invasive 253J and invasive EJ28 having the same doubling time) or by Ki-67 proliferation index within the model. We used the model to test the ability of 4 compounds that interfere with tumour cell–extracellular matrix interactions (suramin, N-acetylcysteine and the urokinase plasminogen activator pathway antagonists Å5 compound and monoclonal antibody Mab 3936) to inhibit invasion. At non-toxic concentrations, all significantly inhibited invasion (P< 0.05), although to varying degrees, suramin and Å5 almost completely and N-acetylcysteine the least. In conclusion, this model shows the urokinase system is important for bladder invasion and can be used to investigate other mechanisms of bladder cancer invasion and also for the testing of intravesical drugs. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Albini A, D’Agostini F, Giunciuglio D, Paglieri I, Balansky R and De Flora S (1995) Inhibition of invasion, gelatinase activity, tumour take and metastasis of malignant cells by N-acetylcysteine. Int J Cancer 61: 121–129
Bajour K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D and Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularisation. Nature Med 4: 923–928
Behrendt N, Ronne E and Dano K (1993) Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J Biol Chem 268: 5985–5989
Bhat GJ, Gunaje JJ and Idell S (1999) Urokinase-type plasminogen activator induces tyrosine phosphorylation of a 78-kDa protein in H-157 cells. Am J Physiol 277: L301–L309
Booth C, Harnden P, Trejdosiewicz LK, Scriven S, Selby PJ and Southgate J (1997) Stromal and vascular invasion in an human in vitro bladder cancer model. Lab Invest 76: 843–857
Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P and Ferrara N (1998) Neutralising anti vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma microtumours in vivo. Prostate 35: 1–10
Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH and Cheresh DA (1995) Antiintegrin αvβ3 blocks human breast cancer growth. J Clin Invest 96: 1815–1822
Chern H-D, Becich MJ, Persad RA, Romkes M, Smith P, Collins C, Li Y-H and Branch RA (1996) Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins. J Urol 156: 1846–1849
Conese M and Blasi F (1995) The urokinase/urokinase-receptor system and cancer invasion. Baillières Clin Haematol 8: 365–389
Cook GP and Hampton JA (1997) Effects of ibuprofen on the in vitro invasiveness of a human transitional cell carcinoma. Anticancer Res 17: 365–368
Crew JP, O’Brien T, Bradburn M, Fuggle S, Cranston D and Harris AL (1997) Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57: 5281–5285
Davies G, Jiang WG and Mason MD (1999) Cell–cell adhesion molecules and their associated proteins in bladder cancer cells and their role in mitogen induced cell–cell dissociation and invasion. Anticancer Res 19: 547–552
Dickinson AJ, Savage PB, Newcomb PV, Lodge R and Sibley GN (1995) The expression of urokinase, its receptor and plasminogen activator inhibitor-1 in bladder cancer (abstract). J Urol 153: 406A
Eisenberger M, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski EG, Lowitt MH, Jacobs SC and Egorin MJ (1993) Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 85: 611–621
Elliot AY, Cleveland P, Cervenka J, Castro AE, Stein N, Hakala TR and Fraley EE (1974) Characterisation of a cell line from human transitional cell cancer of the urinary tract. J Natl Cancer Inst 53: 1341–1349
Fadl-Elmula I, Gorunova L, Mandahl N, Elfving P, Lundgren R, Mitelman F and Heim S (1999) Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding. Br J Cancer 81: 6–12
Folkman J (1990) What is the evidence that tumours are angiogenesis dependent?. J Natl Cancer Inst 82: 4–6
Fujiyama C, Masaki Z and Sugihara H (1995) Reconstruction of the urinary bladder mucosa in three dimensional collagen gel culture: Fibroblast-extracellular matrix interaction of transitional epithelial cells. J Urol 153: 2060–2067
Gilbert HA, Logan SL, Kagan AR, Friedman HA, Cove JK, Fox M, Muldoon TM, Lonni YW, Rowe JH, Cooper JF, Nussbaum H, Chan P, Rao A and Starr A (1978) The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading. J Urol 119: 488–492
Grondhal-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Dano K and Brunner N (1997) Plasminogen activator inhibitor type 1 in cytosolic tumour extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 3: 233–239
Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T and Yoshida O (1993) Matachronous multifocal development of urothelial cancers by intraluminial seeding. Lancet 342: 1087–1088
Harris AL and Neal DE (1992) Bladder cancer-field versus clonal origin. N Engl J Med 326: 759–761
Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y and Sumiyoshi A (1994) The content of urokinase-type plasminogen activator and tumour recurrence in superficial bladder cancer. J Urol 151: 16–20
Hudson ML and McReynolds LM (1997) Urokinase and the urokinase receptor: Association with in vitro invasiveness of human bladder cancer cell lines. J Natl Cancer Inst 89: 709–717
Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T and Goldschmidt-Clermont PJ (1997) Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275: 1649–1652
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844
Lamm DL and Griffith JG (1992) Intravesical therapy: Does it affect the natural history of superficial bladder cancer?. Semin Urol 10: 39–44
Liotta LA, Rao CN and Barsku SH (1983) Tumour invasion and the extracellular matrix. Lab Invest 49: 636–649
Ma D, Gerard RD, Li XY, Alizadeh H and Niederkorn JY (1997) Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 90: 2738–2746
Miyake H, Yoshimura K, Hara I, Eto H, Arakawa S and Kamidono S (1997) Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J Urol 157: 2351–2355
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumour growth. Cell 88: 277–285
Oshinsky GS, Chen Y, Jarett T, Anderson AE and Weiss GH (1995) A model of bladder tumour xenografts in the nude rat. J Urol 154: 1925–1929
Ossowski L (1992) Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase receptor, and interstitial collagenase. Cancer Res 52: 6754–6760
Ossowki L, Russo-Payne H and Wilson EL (1991) Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumour in the nude mouse. Cancer Res 51: 274–281
Parada LF, Tabin CJ, Shih C and Weinber RA (1982) Human EJ bladder carcinoma oncogene is homolgue of Harvey sarcoma virus ras gene. Nature 297: 474–478
Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K and Grondahl-Hansen J (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671–4675
Pesenti E, Sola F, Mongelli N, Grandi M and Spreafico F (1992) Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br J Cancer 66: 367–372
Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F and Dano K (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059–1067
Raghavan D, Shipley WU, Garnick MB, Russell PJ and Richie JP (1990) Biology and management of bladder cancer. N Engl J Med 322: 1129–1138
Rebel JM, Thijssen C, Vermey M, Delouvee A, Zwarthoff EC and Van der Kwast TH (1994) E-cadherin expression determines the mode of replacement of normal urothelium by human bladder carcinoma cells. Cancer Res 54: 5488–5492
Redwood SM, Liu BC, Weiss RE, Hodge DE and Droller MJ (1992) Abrogation of the invasion of human bladder tumour cells by using proetease inhibitor(s). Cancer 69: 1212–1219
Scriven S, Booth C, Thomas DFM, Trejdosiewicz LK and Southgate J (1997) Reconstitution of human urothelium from monolayer cultures. J Urol 158: 1147–1152
See WA, Miller JS and Williams RD (1989) Pathophysiology of transitional tumour cell adherence to sites of urothelial injury in rats: mechanisms mediating intravesical recurrence due to implantation. Cancer Res 49: 5414–5418
Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC and Vogestein B (1992) Clonal origin of bladder cancer. N Engl J Med 326: 737–740
Silverman DT, Rothman N and Devesa SS (1999) Epidemiology of bladder cancer. Bladder Cancer: Biology, Diagnosis and Management, Syrigos KN, Skinner DG (eds), pp 11–55, Oxford University Press: Oxford
Skobe M, Rockwell P, Goldstein N, Vosseler S and Fusenig NE (1997) Halting angiogenesis suppresses carcinoma cell invasion. Nature Med 3: 1222–1227
Soloway MS and Masters S (1980) Urothelial susceptibility to tumour cell implantation – influence of cauterization. Cancer 46: 1158–1163
Southgate J, Hutton KAR, Thomas DFM and Trejdosiewicz LK (1994) Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest 71: 583–594
Theodorescu D, Cornil I, Fernandez BJ and Kerbel RS (1990) Overexpression of normal and mutated forms of HRAS induces orthopic bladder invasion in human transitional cell carcinoma. Proc Natl Acad Sci USA 87: 9047–9051
Theodorescu D, Laderoute KR and Gulding KM (1998) Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell Growth Differ 9: 919–928
Vladovski I, Miao H-Q, Benezra M, Lider O, Bar-Shavit R, Schmidt A and Peretz T (1997) Involvement of the extracellular matrix, heparan sulphate proteoglycans, and heparan sulphate degrading enzymes in angiogenesis and metastatis. Tumour angiogenesis, Bicknell R, Lewis CE, Ferrara N (eds), pp 125–140, Oxford University Press: Oxford
Wallace DMA, Smith JHF, Billington S, Smith MR, Stemplewski HE and Tipton PW (1984) Promotion of bladder tumours by endoscopic procedures in an animal model. Br J Urol 56: 658–662
Walther MM, Figg WD and Lineham WM (1996) Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J Urology 14: S8–S11
Yip L, Dart RC and Hurlbut KM (1998) Intravenous administration of oral N-acetylcysteine. Crit Care Med 26: 40–43
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Fujiyama, C., Jones, A., Fuggle, S. et al. Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion. Br J Cancer 84, 558–564 (2001). https://doi.org/10.1054/bjoc.2000.1641
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1641
Keywords
This article is cited by
-
RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells
Cell Death & Disease (2015)
-
Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells
Histochemistry and Cell Biology (2012)
-
DBC1 re-expression alters the expression of multiple components of the plasminogen pathway
Oncogene (2006)
-
Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma
British Journal of Cancer (2005)
-
Cooperative stimulation of vascular endothelial growth factor expression by hypoxia and reactive oxygen species: the effect of targeting vascular endothelial growth factor and oxidative stress in an orthotopic xenograft model of bladder carcinoma
British Journal of Cancer (2005)